SLPI Antibody (31)

Product Discontinued

SLPI Antibody (31) Summary

• Immunogen: SLPI purified from sputum
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Gene: SLPI
• Purity: Protein G purified

Applications/Dilutions

• Dilutions:
  • Immunoassay
  • Immunohistochemistry
  • Immunohistochemistry-Frozen 1:10-1:500
  • Immunohistochemistry-Paraffin 1:10-1:500
  • Immunoprecipitation 1:10-1:500
  • Western Blot 1:100-1:2000
• Theoretical MW: 11.7 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Packaging, Storage & Formulations

• Storage: Store at 4°C.
• Buffer: PBS
• Preservative: No Preservative
• Purity: Protein G purified

Alternate Names for SLPI Antibody (31)

• ALK1
• ALPProtease inhibitor WAP4
• antileukoproteinase
• BLPISeminal proteinase inhibitor
• HUSI
• HUSI-I
• Mucus proteinase inhibitor
• secretory leukocyte peptidase inhibitor
• secretory leukocyte protease inhibitor (antileukoproteinase)
• Secretory leukocyte protease inhibitor
• SLPI
• WAP four-disulfide core domain protein 4
• WAP4HUSI-1
• WFDC4MPI

Background

Position of the Chimera RNAi. The related RNAi products listed were designed from different accesion number but sharing the same RNAi sequence. Chimera RNA interference (chimera RNAi) is process by which small interfering RNA/DNA chimera triggers the destruction of mRNA for the original gene. The discovery work, design, and application of chimera RNAi has been pioneered by Professor Kaoru Saigo and Dr. Kumiko Ui-Tei at the University of Tokyo. Chimera RNAi has many advantages over the conventional siRNAs. First, it has been demonstrated to have reliable knock-down for over 10,000 human genes. Because the human genome is composed of an intricate, genetic network, chimera RNAi's unique design has successfully obviated the off-target effects including microRNA-based influence. Another advantage of the chimera RNAi technology is its effectiveness at low concentrations (0.5nM to 5nM); only mRNA is destroyed so genomic genes are not affected. Finally, having both the sense and anti-sense strands consisting RNA/DNA chimera, it offers much greater compound stability for streamlining in vitro and in vivo assays and applications while minimizing interferon induction and other adverse reactions.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: SLPI